Summary
Penbutolol (Hoe 893 d), a long-acting non-selective beta-adrenoceptor blocking agent, was given once daily to 23 patients with primary hypertension, WHO Stages I–II. The dose (50–100 mg) needed to achieve the therapeutic goal, i.e. supine diastolic BP<95 mm Hg, was titrated individually. On a daily dose of penbutolol 83±19 mg (mean±SD) blood pressure (BP, mean±SD) fell from 180±21/112±8 mmHg on placebo to 154±25/94±14 mmHg. 18 patients who reached the therapeutic goal (responders) continued in a double blind, cross-over study versus placebo, during which the supine BP fell on average 20/10 mmHg on the same dose of penbutolol, and 2/1 mmHg on placebo. Plasma concentrations (mean±SD) of free 0.10±0.07 µg/ml) and total (2.02±1.39 µg/ml) penbutolol did not differ between responders and nonresponders, and were not correlated with the fall in BP. Side effects were mild and mostly well tolerated. One patient developed dermatitis and another an elevation of liver enzymes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Härtfelder G, Lessenich H, Schmitt K (1972) Penbutolol (Hoe 893 d), ein neues, stark wirksames β-Sympatholytikum mit langer Wirkungsdauer. Arzneim-Forsch 22:930–932
Kaiser J, Härtfelder G, Lindner E, Schölkens B (1980) Zur Pharmakologie des β-Rezeptorenblockers Penbutolol. Arzneim-Forsch 30 (I):420–427
Kaiser J (1980) Untersuchungen zur Spezifizität der Wirkung von Penbutolol und Propranolol unter Berücksichtigung der optischen Isomeren. Arzneim-Forsch 30 (I):427–432
Nyberg G, Wilhelmsson C, Vedin A (1979) The intrinsic sympathomimetic activity of penbutolol. Eur J Clin Pharmacol 16:381–386
Guidicelli JF, Richer C, Chauvin M, Idrissi N, Berdeaux A (1977) Comparative β-adrenoceptor blocking effects and pharmacokinetics of penbutolol and propranolol in man. Br J Clin Pharmacol 4:135–140
Sharma PL, Sapru RP (1978) Comparative potency of intravenous penbutolol and propranolol in man. Int J Clin Pharmacol 16:83–85
Hajdú P, Damm D (1979) Physico-chemical and analytical studies of penbutolol. Arzneim-Forsch 29:602–606
Vallner JJ, Jun HW, Needham TE, Stewart JT, Brown W, Frazer H, Honigberg JL (1977) Plasma level studies of penbutolol after oral dose in man. J Clin Pharmacol 17:231–236
Jun HW, Hayes SL, Wallner JJ, Honigberg JL, Rojos AE, Stewart JT (1979) Plasma level profiles and clinical response of penbutolol after three different single oral doses in man. J Clin Pharmacol 19:415–423
Hansson BG, Hökfelt B (1975) Long term treatment of moderate hypertension with penbutolol (Hoe 893 d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary aldosterone under basal conditions and following exercise. Eur J Clin Pharmacol 9:9–19
Yajnik VH, Nandi JS, Patel SC, Doshi HV, Patel SH (1977) Penbutolol in hypertension: A pilot study with single daily doses. J Int Med Res 5:236–242
Sainani GS, Shah GM, Nandi JS, Gulati RB (1977) A pilot study of once-daily penbutolol in hypertension. Pharmacotherapy 1:493–497
Frick MH, Hartikainen M, Pörsti P (1978) Penbutolol a new non-selective β-adrenergic blocking compound in the treatment of hypertension. A comparison with propranolol. Ann Clin Res 10:105–106
Cangiano JL, Ayala JM, Boksay IJE, Martinez-Maldonado M (1979) Penbutolol — a new β-blocker in the treatment of moderate essential hypertension. J Clin Pharmacol 7:384–389
Lund-Johansen P (1979) Long-term hemodynamic effects of penbutolol at rest and during exercise in essential hypertension. Eur J Clin Pharmacol 16:149–153
Jonsell S (1939) A method for the determination of the heart size by teleroentgenography (a heart volume index). Acta Radiol 20:325–340
Simpson FO (1974) Beta-adrenergic receptor blocking drugs in hypertension. Drugs 7:85–105
Heel RC, Brogden RN, Speight TM, Avery GS (1981) Penbutolol: A preliminary review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 22:1–25
Prichard BNC, Tuckman J (1977) Management and mechanisms of drug treatment of hypertension. In: Genest J (ed) Hypertension. McGraw-Hill, London
Sapru RP, Sharma PL (1978) The effect on myocardial contractility of a new β-adrenergic receptor blocking drug, penbutolol. Br J Clin Pharmacol 6:515–520
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Öhman, K.P., Asplund, J., Landahl, S. et al. Penbutolol (Hoe 893 d) in primary hypertension. Eur J Clin Pharmacol 22, 95–99 (1982). https://doi.org/10.1007/BF00542451
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542451